Hormone Replacement Therapy
Have you benefited from compounded hormone therapy?
Access to your medication may be at risk.
The FDA looks to be making a move that could keep millions of people from using this critical therapy.
Last year, the agency paid the National Academies of Science, Engineering, & Medicine to do a study of the effectiveness of compounded hormone therapy (cBHT). The study concluded that there isn't much clinical evidence for or against its use. But then NASEM recommended that cBHT be restricted anyway.
Millions of Americans use cBHT every day and rely on it. The NASEM study didn't ask the most important question: Does cBHT work for patients? May physicians and patients say that it does.
The FDA is using that study to consider limiting compounded hormone therapy.
If you or someone you know uses compounded bioidentical hormone therapy, it might not be available any more.
Members of the U.S. House of Representatives have written a joint letter to the FDA commissioner, asking that the agency not limit compounded hormone therapy. You can help protect hormone therapy by asking your member of Congress to sign these letters!
Ask your U.S. House member to sign the joint letter to FDA sponsored by Reps. Pocan, Herrera-Beutler, Cuellar, and Roe.
We've made it easy for you: Click the box below, and you'll find a pre-written message - feel free to customize it - to send to your elected officials. It will take less than two minutes to do it!